Estrogen and progestogen effect on venous thromboembolism in menopausal women

References

• Curb JD, Prentice RL, Bray PF, . Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772–80
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, . Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292: 1573–80
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4–8
   PubMed Web of Science ®Google Scholar
• Barlow DH. HRT and the risk of deep vein thrombosis. Int J Gynaecol Obstet 1997;59(Suppl 1):S29–33
   PubMedGoogle Scholar
• Grady D, Wenger NK, Herrington D, . Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689–96
   PubMed Web of Science ®Google Scholar
• Dinger J, Assmann A, Mohner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36: 123–9
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344–54
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151
   PubMed Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342:d2139
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging 1999;14:323–36
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–97
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, . Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Heiss G, Wallace R, Anderson GL, . Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036–45
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011;70:354–60
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977–80
   PubMed Web of Science ®Google Scholar
• Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796–800
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998;147:387–90
   PubMed Web of Science ®Google Scholar
• Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism – a population-based case-control study. Thromb Haemost 1999;82: 1218–21
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Douketis JD, Julian JA, Kearon C, . Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005;3:943–8
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227–31
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol. Thromb Haemost 1983;49:252
   PubMed Web of Science ®Google Scholar
• Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415–20
   PubMed Web of Science ®Google Scholar
• Hoibraaten E, Os I, Seljeflot I, Andersen TO, Hofstad A, Sandset PM. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the Estrogen in Women with Atherosclerosis Study. Thrombosis Res 2000;98:19–27
   PubMed Web of Science ®Google Scholar
• Marque V, Alhenc-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost 2001;86:713–14
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Lacut K, . Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671–6
   PubMed Web of Science ®Google Scholar
• Post MS, Christella M, Thomassen LG, . Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116–21
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071–8
   PubMed Web of Science ®Google Scholar
• Teede HJ, McGrath BP, Smolich JJ, . Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000;20:1404–9
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, . Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619–25
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643–50
   PubMed Web of Science ®Google Scholar
• Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483–8
   PubMed Web of Science ®Google Scholar
• de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271–6
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007;97: 938–43
   PubMed Web of Science ®Google Scholar
• Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008; 90:642–72
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
   PubMed Web of Science ®Google Scholar
• http://clinicaltrials.gov/ct2/show/NCT00114517 accessed 19 January 2012
   Google Scholar